Top Global Biopharmas Standardize on Veeva China CRM Suite
Rhea-AI Summary
Veeva Systems (NYSE: VEEV) has announced that 6 of the top 20 biopharmas have selected Veeva China CRM Suite for healthcare professional (HCP) engagement in China. The suite is specifically developed in China for China, while adhering to Veeva's global development standards for compliance and quality.
The China-specific solution includes local requirements and technologies, in-country hosting, and compliance with privacy and data export regulations. The suite comprises several applications including China CRM, China Events Management, Approved WeChat, China Engage, and China Campaign Manager.
As part of Veeva Commercial Cloud, the global technology foundation for commercial excellence, the suite integrates seamlessly with other Veeva products such as PromoMats, Network, and OpenData.
Positive
- Market leadership: Dominant position as standard CRM for multinational corporations in China
- Strategic expansion: Secured 6 of top 20 global biopharma clients
- Localized compliance: Full alignment with China's privacy and data requirements
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, VEEV declined 2.32%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
6 of the top 20 biopharmas have chosen Veeva for
"Veeva China CRM Suite is being used by more global biopharmas than any other CRM in
Veeva China CRM Suite is part of Veeva Commercial Cloud, the global technology foundation for commercial excellence. Veeva China CRM Suite includes
Additional Information
For more on Veeva China CRM Suite, visit: veeva.com/cn/veeva-china-crm-suite-en
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
| |
Lotus Cai |
View original content to download multimedia:https://www.prnewswire.com/news-releases/top-global-biopharmas-standardize-on-veeva-china-crm-suite-302389248.html
SOURCE Veeva Systems